RR DLBCL; PD-1; CD20
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| A Phase II Study to Evaluate the Efficacy and Safety of F520 Combined With F007 in Patients With RR DLBCL (NCT05178836) | Shandong New Time Pharmaceutical Co., LTD | 2022-01-01 |
Track RR DLBCL; PD-1; CD20 automatically
Every clearance here is in the API, with alerts when new ones post.